Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Bernhard Hauns"'
Autor:
Christian Buske, Alessandra Tedeschi, Judith Trotman, Ramón García-Sanz, David MacDonald, Veronique Leblond, Beatrice Mahe, Charles Herbaux, Jeffrey V Matous, Constantine S Tam, Leonard T Heffner, Marzia Varettoni, M Lia Palomba, Chaim Shustik, Efstathios Kastritis, Steven P Treon, Jerry Ping, Bernhard Hauns, Israel Arango-Hisijara, Meletios A Dimopoulos
Publikováno v:
Future Oncology. 19:345-353
What is this summary about? This article provides a short summary of 5-year results from the iNNOVATE trial. The original paper was published in the Journal of Clinical Oncology in October 2021. People with Waldenström's macroglobulinemia (WM) were
Autor:
Johann S. de Bono, Bernd Hentsch, Vera Strobel, Bernhard Hauns, Anna Mais, Muyibat Olaleye, Isabel Casamayor, Ann Parker, Rebecca Kristeleit, L. Rhoda Molife, David Olmos, Rohit Lal, Joo Ern Ang, André T. Brunetto
Supplementary figure 1. Plot of resminostat concentration versus degree of HDAC enzyme inhibition at 2 hour post-dose on day 1 for all dose levels using the Hill model.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39630264a00477f0eaf1ad5fce361f3e
https://doi.org/10.1158/1078-0432.22449708
https://doi.org/10.1158/1078-0432.22449708
Autor:
Johann S. de Bono, Bernd Hentsch, Vera Strobel, Bernhard Hauns, Anna Mais, Muyibat Olaleye, Isabel Casamayor, Ann Parker, Rebecca Kristeleit, L. Rhoda Molife, David Olmos, Rohit Lal, Joo Ern Ang, André T. Brunetto
Purpose: This first-in-human dose-escalating trial investigated the safety, tolerability, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, and pharmacodynamics of the novel histone deacetylase (HDAC) inhibitor resminost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ccd977a53f75aaff9fa343237ed1641
https://doi.org/10.1158/1078-0432.c.6521730
https://doi.org/10.1158/1078-0432.c.6521730
Autor:
Shiquan Wu, Shuo Ma, Shachar Peles, Israel Arango-Hisijara, Bernhard Hauns, Kevin A. Kwei, Franck Morschhauser, Elizabeth Chong, Morton Coleman, Graham P. Collins, Sven de Vos, Jacqueline C. Barrientos, Stephen D. Smith, Robert T. Chen, Peter Martin, Catherine Thieblemont, Christopher R. Flowers, Leo W.-K. Cheung, Ariela Noy
Publikováno v:
Blood advances. 4(22)
Advanced marginal zone lymphoma (MZL) is an incurable B-cell malignancy dependent on B-cell receptor signaling. The phase 2 PCYC-1121 study demonstrated the safety and efficacy of single-agent ibrutinib 560 mg/d in 63 patients with relapsed/refractor
Autor:
Dieter Hauschke, T.D. Bethke, Kristin Westphal, Giessmann T, Werner Siegmund, M. David, Anita Weinbrenner, G Lahu, K Zech, Bernhard Hauns, Robert Hermann
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 44:572-579
Objective: Roflumilast is an oral, once-daily phosphodiesterase 4 inhibitor under investigation for the treatment of chronic obstructive pulmonary disease and asthma. In clinical practice, the drug is likely to be co-administered with inhaled broncho
Autor:
Andreas Huennemeyer, Gezim Lahu, Nassr Nassr, Karl Zech, Bernhard Hauns, Robert Hermann, Magnus Ingelman-Sundberg, Oliver von Richter, Anna Westlind-Johnsson
Publikováno v:
Clinical Pharmacology & Therapeutics. 79:339-349
Background The major drug-metabolizing enzyme cytochrome P450 (CYP) 3A4 is genetically conserved. One outlier of Brazilian descent was found in a clinical pharmacokinetic trial exhibiting a 6-fold higher exposure than expected to an investigational d
Autor:
Werner Siegmund, Karl Zech, Anita Weinbrenner, T.D. Bethke, Kristin Westphal, Robert Hermann, Bernhard Hauns, Thomas Giessmann, G Lahu, Felix Reutter
Publikováno v:
Journal of clinical pharmacology. 47(8)
This open-label, randomized, 3-period crossover study evaluated the pharmacokinetic interaction potential of roflumilast and budesonide following repeated coadministration to healthy male subjects (N = 12). Treatments consisted of oral roflumilast 50
Autor:
Richard Fux, Klaus Mörike, T.D. Bethke, Gabriele M. Böhmer, Christoph H. Gleiter, Dietrich Knoerzer, Wilhelm Wurst, Robert Hermann, Michael David, Bernhard Hauns
Publikováno v:
Journal of clinical pharmacology. 47(1)
The dose-proportional, intraindividual, single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor under investigation for chronic obstructive pulmonary disease and asthma, was investigated in healthy
Autor:
Dieter Hauschke, Andreas Hünnemeyer, Robert Hermann, Karl Zech, Bernhard Hauns, Rolf Herzog, T.D. Bethke
Publikováno v:
Journal of clinical pharmacology. 46(10)
This open, randomized, single-dose crossover study investigated effects of a high-fat meal on the pharmacokinetics of roflumilast and its major active N-oxide metabolite. Twelve healthy subjects received oral roflumilast 500 microg (2 x 250 microg) a
Autor:
Karl Zech, Werner Siegmund, T.D. Bethke, Robert Hermann, J. Waitzinger, Andreas Huennemeyer, Bernhard Hauns
Publikováno v:
Journal of Allergy and Clinical Immunology. 113:S222
Rationale Roflumilast is a novel, potent, selective phosphodiesterase 4 (PDE4) inhibitor in clinical development for the treatment of COPD and asthma. Patients with these diseases often receive concomitant medications. Therefore, investigation of pot